Download Newsletter

Multiple myeloma (MM) is a relatively uncommon malignancy, yet it levies a substantial socioeconomic burden. In 2014, there will be an estimated 24,050 new cases of MM, with 11,090 myeloma-related deaths. The cost of the disease to private payers in the US healthcare system is generally higher than that for breast cancer, lung cancer, and other more common malignancies. Recent data have shown that total healthcare costs for 1 episode of antimyeloma therapy and the year that follows range from approximately $112,000 to $159,000.

Last modified: November 25, 2014
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME